Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Peptide-Based Drugs for Cancer Therapies"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Targeting and Design".
Deadline for manuscript submissions: closed (10 May 2023) | Viewed by 15194
Special Issue Editors
Interests: cancer therapy; bioconjugate chemistry; antibody-drug conjugates; peptide chemistry; peptide drug conjugates; peptide therapeutics
Interests: targeted therapy; antibody-drug conjugates; precision medicine
Special Issue Information
Occupying the sweet middle space between small organic molecules and large proteins, peptides have demonstrated several unique advantages as potential drug candidates, including low toxicity, low immunogenicity, high potency and specificity. Moreover, technological developments toward peptide synthesis have improved the feasibility of peptide drug development. Thus, peptide therapeutics represent strong candidates for the growth and innovation of the future pharmaceutical world. In fact, the estimated global revenue of peptide therapeutics is expected to reach USD 50.60 billion by the year 2026. The latest survey of peptide-based drugs shows that more than 80 peptide-based drugs have been approved on the global market up until 2021, with another 155 peptides in various stages of clinical development and 400–600 more in preclinical stages. Notably, employing peptides in cancer treatment and management is one of the most topical directions in drug development. The aim of this Special Issue on “Peptide-Based Drugs for Cancer Therapies” is to emphasize current research efforts towards the development of novel peptide-based therapeutics for oncology.
Dr. Iman Kavianinia
Dr. Makhdoom Sarwar
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- peptide-based anticancer drugs
- peptide nanotherapeutics
- peptide–drug conjugates
- peptide drug design
- peptide-based vaccines
- immunosuppressive peptides
- immune-stimulating peptides